Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422669 · ClinicalTrials.gov registry record · NA
Optimize RV Selective Site Pacing Clinical Trial
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Terminated
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT00422669: Clinical Trial NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00422669 is a NA study that was terminated before completion, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 205 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422669, a NA study, was terminated before completion, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- TERMINATED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of the Optimize RV study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of select site pacing is to improve how the heart contracts when paced in the ventricle. By pacing in select sites, it is possible to better copy the natural pattern of contraction of the heart.
Primary Outcome
Left ventricular ejection fraction (LVEF) will be measured at baseline and two year follow-up for the group of pacing at RV Mid-Septum and the group of pacing at Apex. The change in LVEF from baseline to two year follow-up will be compared between two groups to identify if pacing at selective RV sites (Mid-Septum or Apex) will have a different long term impact on the change in LVEF.
Interventions
- DEVICE Medtronic SelectSecure 3830 Lead
- DEVICE Medtronic Dual-Chamber Pacemaker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | NA |
Why NCT00422669 stopped before completion
NCT00422669 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Medtronic SelectSecure 3830 Lead is the first listed.
NCT00422669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00422669 about?
NCT00422669 is a clinical study titled "Optimize RV Selective Site Pacing Clinical Trial". The purpose of the Optimize RV study is to determine the long-term effect of selective site pacing. Selective site pacing refers to which area of the right ventricle the lead is placed. The goal of select site pacing is to improve how the heart contracts when paced in the ventricle. By pacing in sel...
What is the current status of trial NCT00422669?
This trial is currently terminated. It is a NA study. The enrollment target is 205 participants. The study started on 2007-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00422669?
The interventions under investigation include: Medtronic SelectSecure 3830 Lead (DEVICE), Medtronic Dual-Chamber Pacemaker (DEVICE).
Who is sponsoring clinical trial NCT00422669?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00422669's enrollment target sits among peer trials
205 499th of 2000 higher than 1,501 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia